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Abstract
Patients with diastolic heart failure (HF) i.e. clinical HF with normal or near normal left ventricular
ejection fraction (LVEF) may experience unstable angina pectoris (UAP) due to epicardial
atherosclerotic coronary artery disease (CAD) and/or to subendocardial ischemia, even in the absence
of CAD. However, the risk of UAP among ambulatory diastolic HF patients has not been well studied.
We examined incident hospitalizations due to UAP among 916 diastolic HF (LVEF >45%) patients
without significant valvular heart disease and 6800 systolic HF (LVEF ≤45%) patients in the Digitalis
Investigation Group trial. During a 38-month median follow-up, 12% (797/6,800) of systolic HF
patients (incidence rate, 435/10,000 person-years) and 15% (138/916) of diastolic HF patients
(incidence rate, 536/10,000 person-years) were hospitalized for UAP (adjusted hazard ratio for
diastolic HF, 1.22; 95% confidence interval, 1.02–1.47; p=0.032). There was a graded increase in
incident hospital admissions for UAP with increasing LVEF. Hospitalizations for UAP occurred in
11% (520/4,808; incidence rate, 407/10,000 person-years), 14% (355/2556; incidence rate,
496/10,000 person-years) and 17% (60/352; incidence rate, 613/10,000 person-years) of HF patients,
respectively, with LVEF <35%, 35–55%, and >55%. Compared with HF patients with LVEF <35%,
the adjusted hazard ratios (95% confidence intervals) for UAP hospitalization in those with LVEF
35–55% and >55% were respectively 1.17 (1.02–1.34; p=0.028) and 1.57 (1.20–2.07; p=0.026). In
conclusion, in ambulatory chronic HF patients, higher LVEF was associated with increased risk of
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hospitalizations due to UAP. As in patients with systolic HF, those with diastolic HF should be
routinely evaluated for myocardial ischemia and managed accordingly.
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Diastolic heart failure (HF) is common and often associated with hypertensive heart disease
and left ventricular (LV) hypertrophy, which may lead to subendocardial ischemia and unstable
angina pectoris (UAP), even in the absence of atherosclerotic coronary artery disease (CAD).
1–7 In addition, among diastolic HF patients with CAD, myocardium is likely to be viable
rather than infarcted. Systolic HF patients, on the other hand, may be likely to have less viable
myocardium due to prior myocardial infarction and may therefore be at lower risk for UAP.
5,8,9 These observations suggest that the incidence of UAP may be increased in diastolic HF.
However, the risk of hospitalizations due to UAP in ambulatory patients with chronic diastolic
HF is unknown. The objective of this study, therefore, was to determine the incidence of
hospitalization due to UAP in patients with diastolic HF compared to those with systolic HF.
Methods
Study design and patients
This is a post-hoc retrospective analysis of the Digitalis Investigation Group (DIG) trial.10,
11 Of 7788 participants in the DIG trial, 6800 had systolic HF (LVEF ≤45%) and 988 had
diastolic HF (LVEF >45%). Of the 988 diastolic HF patients, 72 had valvular heart disease as
the primary etiology of their HF and were excluded from this analysis. Most patients were
receiving angiotensin-converting enzyme inhibitors and diuretics. Data on beta-blocker use
were not collected. However, many patients had prior myocardial infarction11 and may have
been receiving beta blockers for this indication.12,13
Assessment of left ventricular ejection fraction
LV ejection fraction (LVEF) was measured upon enrollment into the DIG trial. An LVEF
obtained during the 6 months prior to randomization was accepted if the patient remained stable
during that period.14 LVEF was assessed using two-dimensional echocardiography,
radionuclide ventriculography or contrast left ventriculography, without core laboratory
adjudication. When more than one technique was used to measure LVEF, results of
angiographic or radionuclide measurements were given priority over those from
echocardiography.
Outcomes
Hospitalization due to UAP was a pre-specified secondary outcome in the DIG trial and was
the primary outcome for this analysis. The diagnoses leading to hospitalizations were classified
by DIG investigators but were not centrally adjudicated. Vital status was collected up to
December 31, 1995 and was ascertained for 99% of the patients.
Statistical analysis
We calculated incidence rates for UAP hospitalization for patients with systolic and diastolic
HF, and used Kaplan-Meier and bivariate and multivariable Cox regression analyses to
estimate the association of diastolic HF with hospitalization due to UAP. To test if there was
a graded relationship between LVEF and UAP hospitalization, we categorized patients into
three LVEF groups: <35%, 35–55% and >55% and repeated the above analyses. We also
repeated our analysis using LVEF as a continuous variable. To assess for heterogeneity in the
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association between LVEF and UAP hospitalization, we conducted subgroup analyses using
multivariable Cox regression and tested for first-order interactions. All statistical tests were
evaluated using a two-tailed 95% confidence level, and a p value <0.05 was required to reject
the null hypothesis. All data analyses were performed using SPSS version 14.15
Results
Baseline patient characteristics are displayed in Table 1. Patients with diastolic HF were older,
more likely to be women, and to have hypertensive heart disease. Kaplan-Meier plots for time
to first UAP hospitalization are shown in Figure 1. During a median follow-up of 38 months,
UAP hospitalizations occurred in 12% (797/6,800) of systolic HF patients (incidence rate,
435/10,000 person-years) and 15% (138/916) of diastolic HF patients (incidence rate,
536/10,000 person-years). Adjusted hazard ratio for UAP hospitalization for diastolic HF,
when compared with systolic HF was 1.22 (95% confidence interval, 1.02–1.47; p=0.032;
Table 2).
There was a graded increase in hospital admissions due to UAP with increasing LVEF. UAP
hospitalizations occurred in 11% (520/4,808), 14% (355/2556) and 17% (60/352) of patients
respectively with LVEF <35%, 35–55%, and >55% (Table 2). Incidence rates per 10,000
person-years of follow up were 407, 496, and 613 hospital admissions due to UAP,
respectively, in HF patients with LVEF <35%, 35–55%, and >55% (Table 2). Compared to
patients with LVEF <35%, the adjusted hazard ratios (95% confidence intervals) for UAP
hospitalization for those with LVEF 35–55% and >55% were respectively 1.17 (1.02–1.34;
p=0.028) and 1.57 (1.20–2.07; p=0.026). Each percent increase in LVEF was associated with
a significant 0.8% increase in the risk of hospitalization for UAP (Table 2).
Associations between other baseline patient characteristics and hospitalization due to UAP are
displayed in Table 3. The associations of diastolic HF and hospitalization due to UAP in various
subgroups of patients are displayed in Figure 2. There were no significant interactions between
LVEF and any of these subgroups.
Discussion
Our data indicate that over half of ambulatory patients with chronic mild to moderate diastolic
HF enrolled in the DIG trial had CAD, and that compared with systolic HF patients, those with
diastolic HF were at increased risk for hospitalization due to UAP. In addition, female sex,
CAD, prior myocardial infarction, current angina, and diabetes were associated with increased
UAP hospitalizations. These findings are important because diastolic HF patients may not be
routinely evaluated and treated for myocardial ischemia. Furthermore, the prevalence of
diastolic HF is expected to increase over the next several decades. Our data suggest that this
trend could also lead to an increase in hospitalizations for UAP.
A possible explanation for the increased risk of UAP in diastolic HF patients is that these
patients may be more susceptible to myocardial ischemia, in particular subendocardial
ischemia.16–19 Diastolic HF is often associated with concentric LV hypertrophy, which may
in turn be associated with relatively inadequate growth of the coronary arteries, reduction in
coronary flow reserve, and increases in coronary medial thickness and perivascular fibrosis.
20 The ensuing decreased capillary density and increased capillary to myocyte oxygen
diffusion distance make hypertrophied myocardium more susceptible to ischemia, even in the
absence of epicardial coronary atherosclerosis or stenosis.3
CAD, prior myocardial infarction and baseline angina were significantly associated with
increased risk of incident UAP (Table 3). Diastolic HF patients with myocardial ischemia, with
or without CAD, may have more viable myocardium than those with systolic HF, thus
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predisposing them to an increased risk for ischemia and UAP. A recent report by Nijland et al
supports this possibility.21 In that study, HF patients with prior myocardial infarction who had
viable myocardium in the infarct zone experienced more subsequent hospitalizations for UAP
than those without viable myocardium (20% vs. 5%, p=0.006). Moreover, myocardial viability
was the only predictor of UAP.
Our study has several potential limitations. UAP hospitalizations were not centrally
adjudicated. Because beta-blocker use in HF patients has evolved considerably since the DIG
trial was completed, the results of our analysis may not be generalizable to contemporary HF
patients. However, the likely lower use of beta-blockers by DIG participants, in retrospect, has
allowed us to study the association of LVEF with incident UAP in the natural history of HF.
Greater use of beta-blockers in today’s systolic HF patients might further reduce UAP
hospitalizations in this group, resulting in an even wider gap in UAP admissions between
systolic and diastolic HF patients. Since CAD was more prevalent in systolic HF patients in
the DIG trial, it is possible that more systolic HF patients were receiving beta-blockers, thus
accounting for their lower incidence of UAP. However, at the time of the DIG trial, use of beta-
blockers in systolic HF patients was low.22–25 Therefore, our results are unlikely to be
explained entirely by a differential use of beta-blockers in systolic and diastolic HF patients.
Finally, HF patients in this study were relatively young, predominantly men, and had normal
sinus rhythm. The applicability of these findings to elderly HF patients, particularly older
women and patients with atrial fibrillation is uncertain.
Over half of all community-dwelling HF patients have normal or near normal LVEF.4,7,26
Although these patients are often considered less likely to have CAD than those with systolic
HF, the true burden of CAD in this population may be underestimated. The findings of the
current analysis indicate that diastolic HF patients are at greater risk for hospitalization for
UAP than those with systolic HF, and suggest that treatment of CAD in diastolic HF patients
could result in fewer hospitalizations for UAP. Prospective studies are needed to test this
hypothesis.
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Kaplan-Meier plots demonstrating cumulative risk of hospitalizations due to unstable angina
pectoris LVEF = left ventricular ejection fraction
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Hazard ratios (HR) and 95% confidence intervals (CI) for subgroups of patients with diastolic
versus systolic heart failure (HF) ACE=angiotensin-converting enzyme; NYHA=New York
Heart Association
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Table 1
Baseline patient characteristics
Variables Left ventricular ejection fraction P
≤45% (n=6800) >45% (n=916)
Age (years) 63.4 (±10.9) 66.6 (±10.2) <0.0001
Female 1519 (22.3%) 367 (40.1%) <0.0001
Non-white 991 (14.6%) 130 (14.2%) 0.803
Duration of heart failure (months) 30.2 (±36.8) 26.1 (±33.2) 0.005
Etiology of heart failure
 Coronary ischemic 4803 (70.6%) 557 (60.8%)
 Hypertensive 583 (8.6%) 222 (24.2%) <0.0001
 Others 1414 (20.8%) 137 (15.0%)
Prior myocardial infarction 4419 (65.0%) 480 (52.4%) <0.0001
Current angina pectoris 1821 (26.8%) 280 (13.3%) 0.049
Hypertension 3084 (45.4%) 561 (61.2%) <0.0001
Diabetes mellitus 1933 (28.4%) 281 (30.7%) 0.161
Chronic kidney disease* 3042 (44.7%) 441 (48.1%) 0.052
New York Heart Association functional class
 I 907 (13.3%) 176 (19.5%)
 II 3670 (54.0%) 532 (58.1%) <0.0001
 III–IV 2223 (32.7%) 205 (22.4%)
Laboratory findings at randomization
 Serum creatinine (mg/dL) 1.28 (±0.37) 1.26 (±0.39) 0.002
 Pulmonary congestion (current) 1008 (14.8%) 95 (10.4%) <0.0001
 Cardiothoracic ratio >0.5 4194 (61.7%) 450 (49.1%) <0.0001
 Ejection fraction (%) 28.5 (±8.8) 55.1 (±7.9) <0.0001
Medications at randomization
 Pre-trial digoxin use 3017 (44.4%) 312 (34.1%) <0.0001
 Digoxin by randomization 3397 (50.0%) 461 (50.3%) 0.833
 Angiotensin-converting enzyme inhibitors 6422 (94.4%) 795 (86.8%) <0.0001
 Non-potassium sparing diuretics 5325 (78.3%) 691 (75.4%) 0.051
 Nitrates 2898 (42.6%) 374 (40.8%) 0.319
*
Chronic kidney disease was defined as glomerular filtration rate <60 ml/1.73 m2 body surface area
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Table 3
Other predictors of hospitalization due to unstable angina pectoris
Variables Hazard ratio (95% confidence interval)
Unadjusted Adjusted*
Women 1.34 (1.17 – 1.54); p<0.0001 1.40 (1.22 – 1.62); p<0.0001
Coronary ischemic etiology 2.57 (2.15– 3.07); p<0.0001 1.71 (1.35 – 2.16); p<0.0001
Prior myocardial infarction 2.23 (1.90 – 2.61); p<0.0001 1.49 (1.21 – 1.83); p<0.0001
Current angina 2.60 (2.29 – 2.96); p<0.0001 2.08 (1.82 – 2.37); p<0.0001
Diabetes 1.46 (1.28 – 1.67); p<0.0001 1.32 (1.15 – 1.51); p<0.0001
Prior digoxin use 0.77 (0.68 – 0.88); p<0.0001 0.79 (0.69 – 0.91); p=0.001
Current dyspnea at rest 1.39 (1.20 – 1.61); p<0.0001 1.26 (1.09 – 1.47); p=0.002
*
Adjusted for the same covariates as in Table 2
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